ArticleNature reviews. Nephrology2013
APOL1 variants and kidney disease in people of recent African ancestry.
Article in Nature reviews. Nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pan-UK Biobank genome-wide association analyses enhance discovery and resolution of ancestry-enriched effects.Nature genetics · 2025Pooled it
- Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.Kidney international · 2020Pooled it
- An African perspective on the genetic risk of chronic kidney disease: a systematic review.BMC medical genetics · 2018Pooled it
- Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.Kidney international · 2018Pooled it
- Serum creatinine and estimated glomerular filtration rates in HIV positive and negative adults in Ethiopia.PloS one · 2019Trial
- APOL1 kidney disease: a critical narrative review of molecular mechanisms, clinical heterogeneity, and the emerging therapeutic landscape.International urology and nephrology · 2026Review
- Mortality trends involving chronic kidney disease and electrolyte and acid-base disorders in the United States, 1999-2023: a CDC WONDER analysis.Annals of medicine and surgery (2012) · 2026Article
- The distribution of highly deleterious variants across human ancestry groups.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.Kidney international · 2024Article
- Integration of artificial intelligence and multi-omics in kidney diseases.Fundamental research · 2023Review
- GWAS in people of Middle Eastern descent reveals a locus protective of kidney function-a cross-sectional study.BMC medicine · 2022Article
- Article
- APOL1 Risk Variants Associated with Serum Albumin in a Population-Based Cohort Study.American journal of nephrology · 2022Article
- Observational
- Glucocorticoids Induce Partial Remission of Focal Segmental Glomerulosclerosis but Not Interstitial Nephritis in COVID-19 Acute Kidney Injury in an APOL1 Low-Risk Genotype White Patient.The American journal of case reports · 2021Article
- SNPs at 3'UTR of APOL1 and miR-6741-3p target sites associated with kidney diseases more susceptible to SARS-COV-2 infection: in silco and in vitro studies.Mammalian genome : official journal of the International Mammalian Genome Society · 2021Article
- Lysosome function in glomerular health and disease.Cell and tissue research · 2021Review
- Case Report: Renal Failure due to Focal Segmental Glomerulosclerosis in a Patient with Murine Typhus.The American journal of tropical medicine and hygiene · 2020Article
- Alterations in plasma membrane ion channel structures stimulate NLRP3 inflammasome activation in APOL1 risk milieu.The FEBS journal · 2020Article
- Podocyte Lysosome Dysfunction in Chronic Glomerular Diseases.International journal of molecular sciences · 2020Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coding variants within the APOL1 gene have been associated with kidney disease, explaining an association that was previously attributed to variants within the neighbouring MYH9 gene. To better define the role of APOL1 in causing kidney disease in individuals of African ancestry, we performed an extensive survey of the common variation in the region surrounding the APOL1 gene, as seen through the lens of the 1000 Genomes Project. Arguing by exclusion, it is reasonable to conclude that the putative APOL1 causal variants are not proxies for any other variants with more direct roles in kidney disease. Our statistical argument is in part made possible by the exceptionally young age of the APOL1 coding variants coupled with the unusually high rate of genetic recombination surrounding this gene. Although no biological evidence currently exists for the causality of APOL1 variants with kidney disease, our statistical reasoning provides a strong case for causality, and a region to target in future functional studies.
Indexed as
Identifiers
23438974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.